Logo Image
News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademyShortsSponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos|
Clinical Operations & Strategy|
Patient Participation
Advertisement
|Articles|October 1, 2014

ACT 2015 E-Newsletter Schedule

ACT 2015 E-Newsletter Schedule

Advertisement
External Link - article-859062.pdf

Advertisement

Related Content

Advertisement

Why Regulator-Sponsor Alignment Is Critical to Modernizing Trial Execution

ByRob DiCicco,Andy Studna, Senior Editor
July 6th 2026
When clinical trials are designed around the "ideal" engaged patient, the populations who need new treatments most are often the ones quietly screened out before the study even begins. Credit: Stock.Adobe.com/KHAN VECTOR CO.

Operational Pragmatism in ePRO-heavy trials

ByRakshinda Mujeeb, PharmD, CRCP, ACRP-CP
July 6th 2026

How Selective Safety Data Collection Could Make Pragmatic Trials Scalable

ByRob DiCicco
July 2nd 2026

ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation

ByAndy Studna, Senior Editor
July 2nd 2026

Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial

ByElizabeth Walsh, PMP, ACRP-CP
July 1st 2026
Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation

2

Operational Pragmatism in ePRO-heavy trials

3

How Selective Safety Data Collection Could Make Pragmatic Trials Scalable

4

Why Regulator-Sponsor Alignment Is Critical to Modernizing Trial Execution

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us